Stem Cell Clinics

Stem cell medicine's legitimate core is haematopoietic transplantation — bone marrow and cord blood transplants for leukaemias, lymphomas and marrow failure, performed since the late 1960s and past one and a half million procedures worldwide. Add a handful of approved products: limbal stem cells for corneal burns, some cartilage and skin applications, and the expanding gene-modified cell therapies. Everything else — cardiac repair, spinal cord regeneration, neurodegeneration — remains in trials, where results have mostly disappointed a generation of legitimate researchers. The gap between what stem cells might someday do and what they demonstrably do now is the commercial space the clinic industry occupies.

By the early 2020s researchers had catalogued well over two and a half thousand US businesses selling direct-to-consumer 'stem cell' interventions — typically fat-derived cell mixtures, bone marrow concentrates or birth-tissue products injected for arthritis, back pain, COPD, autism, MS, ALS and ageing itself, at cash prices from five to fifty thousand dollars, uncovered by insurance because unproven. The marketing playbook is consistent: patient testimonials in place of trial data, 'your own cells cannot harm you' in place of safety evidence, science-adjacent language ('FDA-registered facility') in place of FDA approval, and urgency. Comparable industries operate in Mexico, Panama, Ukraine and elsewhere, serving an international stem-cell tourism market.

The canonical case: three women blinded or severely visually impaired after a Florida clinic injected fat-derived cells into their eyes for macular degeneration — one procedure, both eyes, same day — published in the New England Journal of Medicine in 2017. Add the 2019 multi-state sepsis cluster from contaminated umbilical-cord-blood products, spinal tumours after intrathecal injections abroad, at least one death in a Florida clinic, and the routine harm nobody counts: five-figure sums extracted from families of children with autism and patients with ALS for interventions with no plausible mechanism. 'Your own cells' can form tumours in the wrong place, embolise, infect — autologous is a sourcing description, not a safety claim.

US clinics exploit two phrases: cell products that are only 'minimally manipulated' and for 'homologous use' (doing in the new location what they did in the old) need no FDA approval. Clinics argued fat cells injected into eyes and spines qualified; the FDA disagreed, won the decisive court cases — Regenerative Sciences in 2014, US Stem Cell Clinic in 2019, upheld on appeal — and ended its enforcement-discretion grace period in 2021. Enforcement since has been real but under-resourced against thousands of businesses, and the industry adapts nomenclature faster than agencies act: as 'stem cell' injections drew scrutiny, the same clinics rebranded around 'exosomes' — unapproved in every indication — and, lately, assorted 'regenerative' peptides.

The customers are not fools: they are people with osteoarthritis medicine manages imperfectly, or diseases it cannot touch — ALS, advanced COPD, autism — exercising the entirely human refusal to accept 'nothing more can be done'. The clinics sell hope in the gap that honest medicine leaves open, and mockery of patients is both cruel and strategically useless. The defensible answer is the boring one: expanding access to legitimate trials (a genuine option — registries are public), straight talk about what regenerative medicine can and cannot yet do, and enforcement aimed at sellers rather than buyers. Right-to-try rhetoric deserves one clarification: those laws concern investigational drugs in real development pipelines, not cash-price injections that will never be tested.

For blood cancers and marrow failure, stem cell transplantation is established medicine through accredited transplant centres. For everything a storefront clinic sells — joints, spines, lungs, brains, ageing — the evidence is absent, the price is cash, and the risk is real and documented. The reliable red flags: payment up front for an unproven use, testimonials instead of trial citations, one clinic treating twenty unrelated diseases, 'FDA-registered' language, and any claim that your own cells are inherently safe. A legitimate experimental therapy enrols you in a registered trial and rarely bills you for the product; a business that does the opposite has told you what it is.